Form 4: Amgen EVP Jonathan P. Graham Reports Acquisition of Common Stock and Holdings of Restricted Stock Units
SEC Form 4 Filing
Jonathan P. Graham, EVP & General Counsel & Secretary of Amgen Inc., reports the acquisition of 11,760 shares of common stock and holdings of 39,925 shares, including restricted stock units (RSUs) and dividend equivalents (DEs).
Summary
- On March 6, 2024, Jonathan P. Graham, an executive at Amgen Inc., reported a transaction involving the company's common stock.
- Graham acquired 11,760 shares of Amgen common stock at a price of $0.
- Following this transaction, Graham's total holdings include 39,925 shares of common stock.
- This total includes restricted stock units (RSUs) that will vest at various dates in the future.
- It also includes dividend equivalents (DEs) that are credited on unvested RSUs and paid out in shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing detailing stock transactions. The acquisition of shares by an executive is generally viewed as a slightly positive sign, but it's not a strong indicator of future performance.
Positives
- The acquisition of shares by an executive could be seen as a positive signal, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but it does detail the vesting schedule for RSUs, indicating future stock awards.
Industry Context
Executive stock ownership is a common practice in publicly traded companies like Amgen. These filings are standard disclosures required by the SEC to ensure transparency in insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- Companies like Johnson & Johnson, Pfizer, and Merck also utilize similar equity-based compensation strategies for their executives.
- The vesting schedules and terms of these equity grants are typically benchmarked against industry peers to remain competitive in attracting and retaining talent.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.
- Employees may view executive stock ownership as a sign of stability and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of transaction: Acquisition of common stock. |
| 03/07/2024 | Date of signature: Filing date of the Form 4. |
| 04/30/2024 | Vesting date for 1,253 RSUs. |
| 04/30/2025 | Vesting date for 1,291 RSUs. |
| 05/02/2024 | Vesting date for 1,114 RSUs. |
| 05/02/2025 | Vesting date for 1,114 RSUs and 1,118 RSUs. |
| 05/02/2026 | Vesting date for 1,149 RSUs and 1,119 RSUs. |
| 05/02/2027 | Vesting date for 1,153 RSUs. |
| 05/05/2024 | Vesting date for 1,122 RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.